Last reviewed · How we verify

Carboplatin-Taxol-Radiotherapy

Hospices Civils de Lyon · Phase 2 active Small molecule

Carboplatin-Taxol-Radiotherapy is a Platinum-based chemotherapy, Microtubule inhibitor, Radiation therapy Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 2 development for Advanced ovarian cancer, Small cell lung cancer.

Carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication, while Taxol (paclitaxel) is a microtubule inhibitor that prevents cell division. Radiotherapy uses ionizing radiation to kill cancer cells.

Carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication, while Taxol (paclitaxel) is a microtubule inhibitor that prevents cell division. Radiotherapy uses ionizing radiation to kill cancer cells. Used for Advanced ovarian cancer, Small cell lung cancer.

At a glance

Generic nameCarboplatin-Taxol-Radiotherapy
SponsorHospices Civils de Lyon
Drug classPlatinum-based chemotherapy, Microtubule inhibitor, Radiation therapy
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Carboplatin works by forming platinum-DNA adducts, which prevent DNA replication and transcription. Taxol, on the other hand, stabilizes microtubules, preventing their disassembly and thereby blocking cell division. Radiotherapy induces DNA damage and apoptosis in cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Carboplatin-Taxol-Radiotherapy

What is Carboplatin-Taxol-Radiotherapy?

Carboplatin-Taxol-Radiotherapy is a Platinum-based chemotherapy, Microtubule inhibitor, Radiation therapy drug developed by Hospices Civils de Lyon, indicated for Advanced ovarian cancer, Small cell lung cancer.

How does Carboplatin-Taxol-Radiotherapy work?

Carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication, while Taxol (paclitaxel) is a microtubule inhibitor that prevents cell division. Radiotherapy uses ionizing radiation to kill cancer cells.

What is Carboplatin-Taxol-Radiotherapy used for?

Carboplatin-Taxol-Radiotherapy is indicated for Advanced ovarian cancer, Small cell lung cancer.

Who makes Carboplatin-Taxol-Radiotherapy?

Carboplatin-Taxol-Radiotherapy is developed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

What drug class is Carboplatin-Taxol-Radiotherapy in?

Carboplatin-Taxol-Radiotherapy belongs to the Platinum-based chemotherapy, Microtubule inhibitor, Radiation therapy class. See all Platinum-based chemotherapy, Microtubule inhibitor, Radiation therapy drugs at /class/platinum-based-chemotherapy-microtubule-inhibitor-radiation-therapy.

What development phase is Carboplatin-Taxol-Radiotherapy in?

Carboplatin-Taxol-Radiotherapy is in Phase 2.

What are the side effects of Carboplatin-Taxol-Radiotherapy?

Common side effects of Carboplatin-Taxol-Radiotherapy include Myelosuppression, Neutropenia, Nausea and vomiting, Diarrhea, Fatigue.

Related